Together with our clinical research and enterprise partners, we develop innovative, market driven, wearable sensor solutions that address some of healthcare’s biggest challenges.
Subscribe to learn about recent BioSensics developments and product releases.
BioSensics has received over $2.5M in grant funding from the NIH to develop a novel telecare solution for Huntington’s disease [press release].
BioSensics was awarded an additional $1.2M to develop a fracture risk test for patients with bone cancer based on skeletal CT scans.
BioSensics has been recognized as one of the 100 most innovative digital health companies in the world by the Journal of mHealth.